Logo image of NBY

NOVABAY PHARMACEUTICALS INC (NBY) Stock Fundamental Analysis

NYSEARCA:NBY - NYSE Arca - US66987P4090 - Common Stock - Currency: USD

0.565  -0.02 (-3.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NBY. NBY was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBY have multiple concerns. NBY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NBY has reported negative net income.
In the past year NBY has reported a negative cash flow from operations.
In the past 5 years NBY always reported negative net income.
In the past 5 years NBY always reported negative operating cash flow.
NBY Yearly Net Income VS EBIT VS OCF VS FCFNBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

NBY has a Return On Assets of -251.48%. This is amonst the worse of the industry: NBY underperforms 90.40% of its industry peers.
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROIC N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBY Yearly ROA, ROE, ROICNBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K 6K

1.3 Margins

NBY's Gross Margin of 66.26% is fine compared to the rest of the industry. NBY outperforms 71.21% of its industry peers.
In the last couple of years the Gross Margin of NBY has declined.
NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
NBY Yearly Profit, Operating, Gross MarginsNBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

0

2. Health

2.1 Basic Checks

NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NBY has more shares outstanding
The number of shares outstanding for NBY has been increased compared to 5 years ago.
NBY has a worse debt/assets ratio than last year.
NBY Yearly Shares OutstandingNBY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
NBY Yearly Total Debt VS Total AssetsNBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -76.71, we must say that NBY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -76.71, NBY is doing worse than 92.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -76.71
ROIC/WACCN/A
WACC11.26%
NBY Yearly LT Debt VS Equity VS FCFNBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 0.68 indicates that NBY may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.68, NBY is doing worse than 90.40% of the companies in the same industry.
A Quick Ratio of 0.41 indicates that NBY may have some problems paying its short term obligations.
With a Quick ratio value of 0.41, NBY is not doing good in the industry: 91.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.41
NBY Yearly Current Assets VS Current LiabilitesNBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.82% over the past year.
Looking at the last year, NBY shows a very negative growth in Revenue. The Revenue has decreased by -33.58% in the last year.
The Revenue has been growing by 8.19% on average over the past years. This is quite good.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%

3.2 Future

Based on estimates for the next years, NBY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.55% on average per year.
The Revenue is expected to grow by 21.46% on average over the next years. This is a very strong growth
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NBY Yearly Revenue VS EstimatesNBY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NBY Yearly EPS VS EstimatesNBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K -8K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NBY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBY Price Earnings VS Forward Price EarningsNBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBY Per share dataNBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as NBY's earnings are expected to grow with 31.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NBY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (4/23/2025, 12:53:22 PM)

0.565

-0.02 (-3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners16.13%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0.95%
Market Cap3.29M
Analysts80
Price Target0.87 (53.98%)
Short Float %1.82%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)-77.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS1.68
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.26%
FCFM N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.41
Altman-Z -76.71
F-Score4
WACC11.26%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A